吡嗪酰胺、丙磺舒和苯溴马隆对氧嘌呤醇肾排泄的影响。
Effects of pyrazinamide, probenecid, and benzbromarone on renal excretion of oxypurinol.
作者信息
Yamamoto T, Moriwaki Y, Takahashi S, Suda M, Higashino K
机构信息
Third Department of Internal Medicine, Hyogo College of Medicine, Japan.
出版信息
Ann Rheum Dis. 1991 Sep;50(9):631-3. doi: 10.1136/ard.50.9.631.
Abstract
The effects of pyrazinamide, probenecid, and benzbromarone on renal excretion of oxypurinol were investigated. Pyrazinamide decreased the mean (SEM) fractional clearance of oxypurinol from 19.2 (2.1) to 8.8 (1.5). Probenecid increased the fractional clearance of oxypurinol from 14.1 (3.5) to 24.8 (4.1). Benzbromarone increased the fractional clearance of oxypurinol from 15.6 (2.3) to 33.8 (2.8). These results suggest that oxypurinol may be secreted by 'an organic acid system' and that oxypurinol is reabsorbed at a putative postsecretory site of the renal tubules.
摘要
研究了吡嗪酰胺、丙磺舒和苯溴马隆对氧嘌呤醇肾排泄的影响。吡嗪酰胺使氧嘌呤醇的平均（标准误）分数清除率从19.2（2.1）降至8.8（1.5）。丙磺舒使氧嘌呤醇的分数清除率从14.1（3.5）增至24.8（4.1）。苯溴马隆使氧嘌呤醇的分数清除率从15.6（2.3）增至33.8（2.8）。这些结果表明，氧嘌呤醇可能通过“有机酸系统”分泌，且氧嘌呤醇在肾小管假定的分泌后部位被重吸收。
相似文献
1
Effects of pyrazinamide, probenecid, and benzbromarone on renal excretion of oxypurinol.吡嗪酰胺、丙磺舒和苯溴马隆对氧嘌呤醇肾排泄的影响。
Ann Rheum Dis. 1991 Sep;50(9):631-3. doi: 10.1136/ard.50.9.631.
2
Renal excretions of oxypurinol and oxypurines--effects of pyrazinamide, probenecid and benzbromarone.
Adv Exp Med Biol. 1989;253A:277-81. doi: 10.1007/978-1-4684-5673-8_46.
3
Renal excretion of purine bases. Effects of probenecid, benzbromarone and pyrazinamide.嘌呤碱的肾脏排泄。丙磺舒、苯溴马隆和吡嗪酰胺的作用。
Nephron. 1988;48(2):116-20. doi: 10.1159/000184888.
4
Renal excretion of purine bases--effects of probenecid, benzbromarone and pyrazinamide.
Adv Exp Med Biol. 1989;253A:283-7. doi: 10.1007/978-1-4684-5673-8_47.
5
Pharmacologic evaluation of the renal handling of uric acid and oxypurines.尿酸和氧嘌呤肾处理的药理学评估。
Nihon Jinzo Gakkai Shi. 1994 Nov;36(11):1268-75.
6
Evidence for a postsecretory reabsorptive site for uric acid in man.人体尿酸分泌后重吸收部位的证据。
J Clin Invest. 1973 Jun;52(6):1491-9. doi: 10.1172/JCI107323.
7
Two cases in whom pyrazinamide does not inhibit the uricosuric action of benzbromarone.
Nephron. 1992;61(4):432-4. doi: 10.1159/000186962.
8
[Effect of exercise on urate excretion].[运动对尿酸排泄的影响]
Nihon Seirigaku Zasshi. 1989;51(7):208-20.
9
Analysis of uric acid transport in renal tubules using benzbromarone and pyrazinamide.使用苯溴马隆和吡嗪酰胺对肾小管尿酸转运的分析。
Int J Clin Pharmacol Ther Toxicol. 1990 Feb;28(2):84-8.
10
Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone.尿酸转运体参与了由促尿酸排泄药苯溴马隆诱导的黄嘌呤氧化酶抑制剂奥昔嘌醇肾脏清除率增加的过程。
Drug Metab Dispos. 2005 Dec;33(12):1791-5. doi: 10.1124/dmd.105.006056. Epub 2005 Aug 31.
引用本文的文献
1
Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus.降尿酸治疗与 2 型糖尿病风险的关联。
PLoS One. 2019 Jan 7;14(1):e0210085. doi: 10.1371/journal.pone.0210085. eCollection 2019.
2
Allopurinol, benzbromarone, or a combination in treating patients with gout: analysis of a series of outpatients.别嘌醇、苯溴马隆或两者联合治疗痛风患者：一系列门诊患者分析
Int J Rheumatol. 2014;2014:263720. doi: 10.1155/2014/263720. Epub 2014 Feb 12.
3
Trends in physician diagnosed gout and gout therapies in the US: results from the national ambulatory health care surveys 1993 to 2009.美国医生诊断的痛风及痛风治疗趋势：1993年至2009年国家门诊医疗调查结果
Arthritis Res Ther. 2013 Nov 6;15(6):R181. doi: 10.1186/ar4370.
4
A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?苯溴马隆治疗痛风的获益-风险评估。其退市符合患者的最大利益吗？
Drug Saf. 2008;31(8):643-65. doi: 10.2165/00002018-200831080-00002.
5
Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects.别嘌醇与丙磺舒在健康受试者中的药代动力学和药效学相互作用。
Clin Pharmacokinet. 2008;47(2):111-8. doi: 10.2165/00003088-200847020-00004.
6
Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.别嘌醇和氧嘌呤醇的临床药代动力学与药效学
Clin Pharmacokinet. 2007;46(8):623-44. doi: 10.2165/00003088-200746080-00001.
7
Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients.别嘌醇及别嘌醇-丙磺舒对曾用苯溴马隆治疗的痛风患者的生化疗效。
Clin Rheumatol. 2007 Sep;26(9):1459-65. doi: 10.1007/s10067-006-0528-3. Epub 2007 Feb 17.
本文引用的文献
1
Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide.
Eur J Clin Pharmacol. 1982;22(1):77-84. doi: 10.1007/BF00606429.
2
Allopurinol kinetics and bioavailability. Intravenous, oral and rectal administration.
Cancer Chemother Pharmacol. 1982;8(1):93-8. doi: 10.1007/BF00292878.
3
Hypouricemia due to renal urate wasting. Two types of tubular transport defect.由于肾脏尿酸盐排泄导致的低尿酸血症。两种类型的肾小管转运缺陷。
Nephron. 1982;30(1):39-44. doi: 10.1159/000182430.
4
[Uric acid-lowering effect of a combination of benzbromarone and allopurinol--studies under standardized dietary conditions].
Arzneimittelforschung. 1983;33(12):1687-91.
5
Renal handling of uric acid in normal subjects by means of the pyrazinamide and probenecid tests.通过吡嗪酰胺和丙磺舒试验研究正常受试者尿酸的肾脏处理情况。
Nephron. 1983;35(3):183-6. doi: 10.1159/000183071.
6
Does benzbromarone in therapeutic doses raise renal excretion of oxipurinol?治疗剂量的苯溴马隆是否会提高氧嘌呤醇的肾脏排泄量？
Klin Wochenschr. 1984 Dec 17;62(24):1170-2. doi: 10.1007/BF01712184.
7
On the metabolism of allopurinol. Formation of allopurinol-1-riboside in purine nucleoside phosphorylase deficiency.
Biochem Pharmacol. 1983 Jul 15;32(14):2167-74. doi: 10.1016/0006-2952(83)90222-8.
8
Renal clearance of oxipurinol, the chief metabolite of allopurinol.
Am J Med. 1968 Jul;45(1):69-77. doi: 10.1016/0002-9343(68)90008-9.
9
Origins of the uricosuric response.促尿酸排泄反应的起源。
J Clin Invest. 1973 Jun;52(6):1368-75. doi: 10.1172/JCI107309.
10
The effect of dietary protein on the clearance of allopurinol and oxypurinol.膳食蛋白质对别嘌醇和氧嘌呤醇清除率的影响。
N Engl J Med. 1985 Sep 26;313(13):771-6. doi: 10.1056/NEJM198509263131302.
Zotero 插件